Alamar Biosciences, Inc.
Nasdaq · CIK 0002104204 · Fiscal year end 1231
Latest reported period: Latest published period
Revenue
$26.0M
Cost Of Revenue
$11.6M
Gross Profit
$14.5M
Recent financials
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $26.0M | - | - |
| Cost Of Revenue | $11.6M | - | - |
| Gross Profit | $14.5M | - | - |
| Operating Income | $-12.3M | - | - |
| Net Income | $-21.3M | - | - |
| Eps Basic | -1.74 | - | - |
| Eps Diluted | -1.74 | - | - |
| Cash And Equivalents | $64.6M | - | - |
| Total Assets | $186.5M | - | - |
| Total Liabilities | $129.5M | - | - |
| Shareholders Equity | $-178.1M | - | - |
| Operating Cash Flow | $-20.3M | - | - |
| Capital Expenditures | $600,000 | - | - |
Latest filings
| Form | Company | Filed | Accession |
|---|---|---|---|
| 10-Q | Alamar Biosciences, Inc. | 2026-05-08 | 0001193125-26-213424 |
| 4 | Alamar Biosciences, Inc. | 2026-04-22 | 0001231919-26-000392 |
| 4 | Alamar Biosciences, Inc. | 2026-04-20 | 0001786386-26-000006 |
| 4 | Alamar Biosciences, Inc. | 2026-04-20 | 0001534166-26-000006 |
| 4 | Alamar Biosciences, Inc. | 2026-04-20 | 0001193125-26-164634 |
| 4 | Alamar Biosciences, Inc. | 2026-04-20 | 0002126704-26-000004 |
| 4 | Alamar Biosciences, Inc. | 2026-04-20 | 0002126944-26-000004 |
| 4 | Alamar Biosciences, Inc. | 2026-04-20 | 0002126941-26-000004 |